| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1010967004 |
| P356 | DOI | 10.1007/S00106-009-1909-0 |
| P698 | PubMed publication ID | 19387596 |
| P2093 | author name string | R Knecht | |
| P2860 | cites work | Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours | Q29618396 |
| Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck | Q29619277 | ||
| Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. | Q30591228 | ||
| Individual patient data meta-analyses in head and neck carcinoma: what have we learnt? | Q30986294 | ||
| Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. | Q31102953 | ||
| Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer | Q32034427 | ||
| Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer | Q33332109 | ||
| Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC) | Q33335940 | ||
| RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck | Q33340024 | ||
| Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer | Q33377142 | ||
| Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
| Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer | Q34106818 | ||
| Radiation-induced second cancers: the impact of 3D-CRT and IMRT | Q34190538 | ||
| Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial | Q34265391 | ||
| Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck | Q34287207 | ||
| Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules | Q34320910 | ||
| Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck | Q34533587 | ||
| Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck | Q34563033 | ||
| The expanding role of systemic therapy in head and neck cancer | Q35760433 | ||
| Tirapazamine-cisplatin: the synergy | Q36291599 | ||
| Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology? | Q36304013 | ||
| Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck | Q36500960 | ||
| Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial | Q38515529 | ||
| Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy | Q40587509 | ||
| Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group | Q40933645 | ||
| Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. | Q41530059 | ||
| Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer | Q44071769 | ||
| Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network | Q44106878 | ||
| Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. | Q44260431 | ||
| Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer | Q44276678 | ||
| Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer | Q44674194 | ||
| Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma | Q44681179 | ||
| Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database | Q44849577 | ||
| Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience | Q44995380 | ||
| Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. | Q45152760 | ||
| Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). | Q45206507 | ||
| Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiothera | Q45271712 | ||
| Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience | Q46116207 | ||
| Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck | Q46595210 | ||
| Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer | Q46932585 | ||
| Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study | Q47746681 | ||
| Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. | Q51702694 | ||
| Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. | Q53794992 | ||
| Radiotherapeutic management of surgical recurrences and postoperative residuals in tumors of the head and neck. | Q54713516 | ||
| A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9 | Q56532851 | ||
| Evaluation of the dose for postoperative radiation therapy of head and neck cancer: First report of a prospective randomized trial | Q56532854 | ||
| Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) | Q56532860 | ||
| Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck | Q56532861 | ||
| Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head | Q56688854 | ||
| Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base | Q57949385 | ||
| Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: The Hong Kong experience | Q59647325 | ||
| Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing | Q61771728 | ||
| Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated With Hyperfractionated Radiotherapy | Q61810997 | ||
| Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume | Q62746798 | ||
| Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. | Q65000521 | ||
| Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy | Q67984672 | ||
| Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma | Q71102409 | ||
| Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions | Q71122866 | ||
| Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo | Q72365225 | ||
| Bioreductive metabolism of SR-4233 (WIN 59075) by whole cell suspensions under aerobic and hypoxic conditions: role of the pentose cycle and implications for the mechanism of cytotoxicity observed in air | Q72465057 | ||
| Distant metastases in head and neck cancer patients who achieved loco-regional control | Q72992956 | ||
| Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo | Q73311173 | ||
| Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial | Q73589822 | ||
| Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study | Q73702893 | ||
| Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells | Q74346536 | ||
| Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck | Q74522951 | ||
| Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer | Q74613855 | ||
| Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer | Q74668378 | ||
| Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy? | Q77322308 | ||
| Head and neck cancers | Q80343911 | ||
| Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function | Q80587748 | ||
| Optimal therapy for unresectable stage III non-small-cell lung cancer | Q81023632 | ||
| Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis | Q81474791 | ||
| P433 | issue | 5 | |
| P921 | main subject | head and neck carcinoma | Q18554836 |
| neck cancer | Q18966654 | ||
| head and neck cancer | Q1783924 | ||
| P304 | page(s) | 436-445 | |
| P577 | publication date | 2009-05-01 | |
| P1433 | published in | HNO | Q27711112 |
| P1476 | title | [Radiotherapy, chemotherapy and target therapy for treatment of head and neck cancer : new developments] | |
| P478 | volume | 57 |
| Q35013896 | Incidence and localization of abnormal mucosa findings in patients consulting ENT outpatient clinics and data analysis of a cancer registry. |
| Q36529843 | Systemic therapy strategies for head-neck carcinomas: Current status |
| Q82259668 | [Prevalence of abnormal mucosal findings in patients in HNO practices] |
| Q83335302 | [Recent advances in the treatment of laryngeal and hypopharyngeal carcinoma] |
Search more.